A milestone endorsement for Oxford VR’s business model and scale-up capacity.
Oxford VR (OVR) a global pioneer in evidence-based VR therapy, and an integral collaborator in gameChange, a £4 million project funded by the UK National Institute of Health Research (NIHR) is commencing the first large-scale multi-site trial to test VR therapy treatment for psychosis to advance its roll out by the NHS and Social Care. gameChange demonstrates the real clinical value of OVR’s proprietary development capability which the company has accelerated since its’ 2018 funding round.
Psychosis is a serious mental illness which can affect individuals’ thoughts, feelings and behaviours and can have a big impact on a person’s life leading to anxiety and withdrawal from everyday life.
“We are at a moment of real change in advancing treatment for serious, complex and costly mental health conditions and gameChange will show how the very best psychological science when combined with scaleable, state-of-the-art VR technology can revolutionise treatment and deliver a superior patient experience. gameChange shows that Oxford VR has the know-how and capacity to go beyond the primary care market to create a standard treatment for more challenging and costly mental health conditions.”
The gameChange trial is being led by Daniel Freeman, Professor of Psychology at the University of Oxford. Other collaborators include Oxford University, Oxford Health NHS Foundation Trust, The McPin Foundation, The Royal College of Art, NIHR, MindTech and several NHS mental health trusts.
